Abstract Details

Title Mortality and Functional Outcomes of Thalamic Hemorrhage in the Elderly

Topic Cerebrovascular Disease and Interventional Neurology

Presentation(s) P07 - (-)

Poster/Presentation
Number 237

Objective

Background BACKGROUND: Advanced age is believed to adversely affect the functional outcomes after an intracerebral hemorrhage. But, it's unclear if isolated thalamic hemorrhage in the elderly (age 80 and above) conform to the current perception of poor prognosis.

Design/Methods DESIGN/METHODS: 135 consecutive cases of thalamic hemorrhage admitted to a primary stroke center between 2003 and 2011 were reviewed. The patients were divided by age into two groups (80 years and older; and under 80 years). Clinical, radiographic, and demographic features retrieved from a longitudinal stroke database are compared. Mortality and functional outcome measured by the modified Barthel Index were obtained at 3 months after the stroke.

Results RESULTS: 16.7% (7/42) of patients 80 years and older died as a result of the thalamic hemorrhage compared to 27.8% (22/79; P=0.17) in those younger than 80 years. Older and younger patients had similar mean ICHs (2.1 vs. 1.11); ICH volume (20.43cc vs 13.24cc); mean Graeb scale (3.9 vs 3.59); and initial Glasgow Coma Score (GCS: 12.59 vs 13.09). Functional outcomes in survivors at 3 months did not differ between the two groups: 36.4% (over 80); and 32.3% (under 80) reached pre-stroke functional state.

Conclusions CONCLUSIONS: A lethal outcome after a thalamic hemorrhage in the elderly patient is not always predictable. In fact, there appears to be a trend towards lower mortality in those 80 years and over, despite similar hemorrhage volume, intraventricular hemorrhage, and initial GCS. For survivors, the elderly did just as well as the younger with no apparent difference in functional outcome at three months.

Authors/Disclosures
Nada El-Andary, MD PRESENTER	No disclosure on file
Nathalie M. Goemans, MD (University Hospitals Leuven)	Dr. Goemans has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pfizer. Dr. Goemans has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. Dr. Goemans has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Dr. Goemans has received publishing royalties from a publication relating to health care.
Nora S. Lee, MD	No disclosure on file
	No disclosure on file

��ɫ��

��ɫ��